Literature DB >> 7452665

Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion.

M Masquelier, R Baurain, A Trouet.   

Abstract

The synthesis of amino acid and dipeptide derivatives of daunorubicin (DNR) is described. The binding-affinity parameters for DNA of those derivatives were determined by a spectral titration method. The affinity constants of the amino acid and dipeptide derivatives are, respectively, three and ten times lower than that of DNR. The susceptibility of those derivatives toward lysosomal peptidases was studied. It was found that the Leu and the Ala-Leu derivatives are the most rapidly hydrolyzed into DNR. It is concluded that Leu-DNR and Ala-Leu-DNR could act as prodrugs of DNR, which could be activated inside or in the close vicinity of tumor cells which display a high aminopeptidase activity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7452665     DOI: 10.1021/jm00185a003

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy.

Authors:  Santosh Aryal; Che-Ming Jack Hu; Liangfang Zhang
Journal:  Mol Pharm       Date:  2011-07-06       Impact factor: 4.939

2.  A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

Authors:  A Trouet; M Masquelier; R Baurain; D Deprez-De Campeneere
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

3.  Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.

Authors:  A Zenebergh; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Development of new derivatives of primaquine by association with lysosomotropic carriers.

Authors:  A U Trouet; P Pirson; R Steiger; M Masquelier; R Baurain; J Gillet
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

5.  Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme.

Authors:  E J Franssen; R G van Amsterdam; J Visser; F Moolenaar; D de Zeeuw; D K Meijer
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

6.  Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice.

Authors:  J de Jong; I Klein; A Bast; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.

Authors:  Yasuhiro Tsume; Gordon L Amidon
Journal:  Molecules       Date:  2012-03-26       Impact factor: 4.411

Review 8.  Aminopeptidase N (CD13) as a target for cancer chemotherapy.

Authors:  Malin Wickström; Rolf Larsson; Peter Nygren; Joachim Gullbo
Journal:  Cancer Sci       Date:  2011-01-30       Impact factor: 6.716

9.  The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.

Authors:  E Boven; H R Hendriks; C A Erkelens; H M Pinedo
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.